Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering

Due to the vague symptomatology of the disease and a lack of effective screening methods, most patients with epithelial ovarian cancer (EOC) present late in their disease. Despite advances in chemotherapeutic agents, the prognosis of these patients has uniformly been extremely poor. Although cisplat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria Poplawska, Dibyendu Dutta, Yichun Lee, Seah H. Lim
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Sperm protein 17 tumor antigens epithelial ovarian cancer cell-based immunotherapy immunoengineering Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/1de7433646694abab8d081d7b30f2008
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1de7433646694abab8d081d7b30f2008
record_format	dspace
spelling	oai:doaj.org-article:1de7433646694abab8d081d7b30f20082021-11-14T04:34:26ZSperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering2372-770510.1016/j.omto.2021.10.010https://doaj.org/article/1de7433646694abab8d081d7b30f20082021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2372770521001479https://doaj.org/toc/2372-7705Due to the vague symptomatology of the disease and a lack of effective screening methods, most patients with epithelial ovarian cancer (EOC) present late in their disease. Despite advances in chemotherapeutic agents, the prognosis of these patients has uniformly been extremely poor. Although cisplatin-based chemotherapy regimens induce responses in most of these patients, the patients invariably experience disease progression or relapses. In an attempt to improve the treatment outcome using a different therapeutic approach, immunotherapy was investigated nearly 20 years ago. Many tumor antigens that are potentially suitable for specific immunotherapy were identified, and many immunotherapeutic approaches were attempted. However, although some responses were observed, the results from clinical studies were generally disappointing. Recent advances in immunoengineering and successes observed among patients treated for refractory/relapsed hematologic malignancies have rekindled the interest to revisit specific cellular immunotherapy in EOC. In this review, we provide the rationale for immunotherapy of EOC, discuss the results of some of the historical studies on the use of cellular immunotherapy in EOC, outline the principles of modern immunoengineering that could be applied to treat the disease, and propose the re-evaluation of the cancer-testis antigen, Sperm protein 17, for targeting by using modern immunoengineering technology.Maria PoplawskaDibyendu DuttaYichun LeeSeah H. LimElsevierarticleSperm protein 17tumor antigensepithelial ovarian cancercell-based immunotherapyimmunoengineeringNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENMolecular Therapy: Oncolytics, Vol 23, Iss , Pp 378-386 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Sperm protein 17 tumor antigens epithelial ovarian cancer cell-based immunotherapy immunoengineering Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Sperm protein 17 tumor antigens epithelial ovarian cancer cell-based immunotherapy immunoengineering Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maria Poplawska Dibyendu Dutta Yichun Lee Seah H. Lim Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering
description	Due to the vague symptomatology of the disease and a lack of effective screening methods, most patients with epithelial ovarian cancer (EOC) present late in their disease. Despite advances in chemotherapeutic agents, the prognosis of these patients has uniformly been extremely poor. Although cisplatin-based chemotherapy regimens induce responses in most of these patients, the patients invariably experience disease progression or relapses. In an attempt to improve the treatment outcome using a different therapeutic approach, immunotherapy was investigated nearly 20 years ago. Many tumor antigens that are potentially suitable for specific immunotherapy were identified, and many immunotherapeutic approaches were attempted. However, although some responses were observed, the results from clinical studies were generally disappointing. Recent advances in immunoengineering and successes observed among patients treated for refractory/relapsed hematologic malignancies have rekindled the interest to revisit specific cellular immunotherapy in EOC. In this review, we provide the rationale for immunotherapy of EOC, discuss the results of some of the historical studies on the use of cellular immunotherapy in EOC, outline the principles of modern immunoengineering that could be applied to treat the disease, and propose the re-evaluation of the cancer-testis antigen, Sperm protein 17, for targeting by using modern immunoengineering technology.
format	article
author	Maria Poplawska Dibyendu Dutta Yichun Lee Seah H. Lim
author_facet	Maria Poplawska Dibyendu Dutta Yichun Lee Seah H. Lim
author_sort	Maria Poplawska
title	Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering
title_short	Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering
title_full	Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering
title_fullStr	Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering
title_full_unstemmed	Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering
title_sort	sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/1de7433646694abab8d081d7b30f2008
work_keys_str_mv	AT mariapoplawska spermprotein17targetingforepithelialovariancancertreatmentintheeraofmodernimmunoengineering AT dibyendudutta spermprotein17targetingforepithelialovariancancertreatmentintheeraofmodernimmunoengineering AT yichunlee spermprotein17targetingforepithelialovariancancertreatmentintheeraofmodernimmunoengineering AT seahhlim spermprotein17targetingforepithelialovariancancertreatmentintheeraofmodernimmunoengineering
_version_	1718429883678326784

Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering

Ejemplares similares